Lipella Pharma Reports Positive Phase 2a Data For LP-310 In Oral Lichen Planus; Stock Up

(RTTNews) - Lipella Pharmaceuticals Inc. (LIPO) Tuesday reported positive topline data from Phase 2a study of LP-310 for the treatment of oral lichen planus (OLP). Following the news, the company's shares were more than 65 percent up in pre-market.

OLP is a chronic inflammatory condition that targets mucous membranes in the mouth, causing pain.

In the study, OLP patients were treated with twice-daily dose of 0.25 mg of LP-310. Results from the study showed clinically meaningful reductions in pain, ulceration, and inflammation in patients treated with LP-310. Further, there were no reports of product-related serious adverse events.

A Phase 2a study with higher treatment dose is underway.

Lipella stock had closed at $3.05, down 0.65 percent on Monday. It has traded in the range of $2.21 - 12.00 in the last 1 year.